Novartis won't take 'hint' as German HTA says Gilenya offers little additional benefit
This article was originally published in Scrip
Executive Summary
Novartis's oral MS drug Gilenya (fingolimod) appears to have been 'damned with faint praise' as the German reimbursement process concluded that the drug only demonstrated "a hint of benefit", in comparison with interferon beta treatment and no benefit compared to Teva's Copaxone. Novartis put this down to "teething troubles" in the new German system and hopes that it will be remedied subsequently